Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Medicine and Health Sciences (134)
- Medical Specialties (111)
- Medical Sciences (100)
- Oncology (99)
- Bioinformatics (74)
-
- Biomedical Informatics (72)
- Diseases (32)
- Genetic Phenomena (27)
- Medical Genetics (27)
- Cell and Developmental Biology (22)
- Cancer Biology (21)
- Medical Immunology (15)
- Neoplasms (15)
- Biology (9)
- Public Health (9)
- Biological Phenomena, Cell Phenomena, and Immunity (8)
- Biochemistry, Biophysics, and Structural Biology (6)
- Cell Biology (6)
- Medical Cell Biology (6)
- Otolaryngology (6)
- Otorhinolaryngologic Diseases (6)
- Research Methods in Life Sciences (6)
- Animal Experimentation and Research (5)
- Genetics and Genomics (5)
- Hematology (5)
- Immunity (5)
- Translational Medical Research (5)
- Institution
-
- The Texas Medical Center Library (111)
- Thomas Jefferson University (9)
- Old Dominion University (4)
- University of Louisville (4)
- University of Texas Rio Grande Valley (3)
-
- Virginia Commonwealth University (3)
- Claremont Colleges (2)
- Dartmouth College (2)
- Edith Cowan University (2)
- LSU Health New Orleans (2)
- West Virginia University (2)
- Bowling Green State University (1)
- Louisiana State University (1)
- Munster Technological University (1)
- Rollins College (1)
- Tennessee State University (1)
- University of Connecticut (1)
- University of Kentucky (1)
- University of Nebraska Medical Center (1)
- University of New Mexico (1)
- University of South Carolina (1)
- University of Texas MD Anderson Cancer Center (1)
- Wilfrid Laurier University (1)
- Publication
-
- Faculty, Staff and Student Publications (77)
- Faculty, Staff and Students Publications (17)
- Dissertations and Theses (Open Access) (15)
- Electronic Theses and Dissertations (4)
- Kimmel Cancer Center Faculty Papers (4)
-
- Dartmouth College Ph.D Dissertations (2)
- Graduate Theses, Dissertations, and Problem Reports (ETD) (2)
- Research Symposium (2)
- Research outputs 2014 to 2021 (2)
- School of Medicine Faculty Publications (2)
- Theses and Dissertations (2)
- Bioelectrics Publications (1)
- Biological Sciences Faculty Publications (1)
- Biology Faculty Research (1)
- Biomedical Sciences ETDs (1)
- Biomedical Sciences Theses & Dissertations (1)
- CMC Senior Theses (1)
- Center for Medical Ethics and Health Policy Staff Publications (1)
- Department of Medical Oncology Faculty Papers (1)
- Department of Medicine Faculty Papers (1)
- Department of Medicine Faculty Publications (1)
- Department of Pharmacology, Physiology, and Cancer Biology Faculty Papers (1)
- Department of Radiation Oncology Faculty Papers (1)
- Duncan NRI Faculty and Staff Publications (1)
- Honors Program Theses (1)
- Honors Projects (1)
- Honors Scholar Theses (1)
- International Undergraduate Journal of Health Sciences (1)
- LSU Doctoral Dissertations (1)
- Research Colloquium (1)
- Publication Type
Articles 151 - 156 of 156
Full-Text Articles in Immunotherapy
Immunotherapy In Hepatocellular Cancer Patients With Mild To Severe Liver Dysfunction: Adjunctive Role Of The Albi Grade, David J Pinato, Takahiro Kaneko, Anwaar Saeed, Tiziana Pressiani, Ahmed Kaseb, Yinghong Wang, David Szafron, Tomi Jun, Sirish Dharmapuri, Abdul Rafeh Naqash, Mahvish Muzaffar, Musharraf Navaid, Chieh-Ju Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Hannah Hildebrand, Yehia I Abugabal, Celina Ang, Thomas U Marron, Uqba Khan, Nicola Personeni, Lorenza Rimassa, Yi-Hsiang Huang
Immunotherapy In Hepatocellular Cancer Patients With Mild To Severe Liver Dysfunction: Adjunctive Role Of The Albi Grade, David J Pinato, Takahiro Kaneko, Anwaar Saeed, Tiziana Pressiani, Ahmed Kaseb, Yinghong Wang, David Szafron, Tomi Jun, Sirish Dharmapuri, Abdul Rafeh Naqash, Mahvish Muzaffar, Musharraf Navaid, Chieh-Ju Lee, Anushi Bulumulle, Bo Yu, Sonal Paul, Neil Nimkar, Dominik Bettinger, Hannah Hildebrand, Yehia I Abugabal, Celina Ang, Thomas U Marron, Uqba Khan, Nicola Personeni, Lorenza Rimassa, Yi-Hsiang Huang
Faculty, Staff and Students Publications
Immune checkpoint inhibitors (ICI) have shown positive results in patients with hepatocellular carcinoma (HCC). As liver function contributes to prognosis, its precise assessment is necessary for the safe prescribing and clinical development of ICI in HCC. We tested the accuracy of the albumin-bilirubin (ALBI) grade as an alternative prognostic biomarker to the Child-Turcotte-Pugh (CTP). In a prospectively maintained multi-centre dataset of HCC patients, we assessed safety and efficacy of ICI across varying levels of liver dysfunction described by CTP (A to C) and ALBI grade and evaluated uni- and multi-variable predictors of overall (OS) and post-immunotherapy survival (PIOS). We studied …
Immunotherapy: Therapy Vs. Enhancement, Mariah Daly
Immunotherapy: Therapy Vs. Enhancement, Mariah Daly
Honors Program Theses
The battle against cancer is a long-standing struggle that has resulted in new information and the development of novel medical technologies. Current research aims to figure out a way to reprogram cells and bodily mechanisms to eliminate those cells that are cancerous without destroying healthy cells in the process. Methods which use the body’s own mechanisms, such as immunotherapy, have shown and continue to show potential for specifically targeting cancer cells. Adoptive T cell therapy is one form of immunotherapy that has gained significant attention and focus in the field. Therapies improve conditions up to the normal state of being, …
Identification Of Imiquimod As A Potential Combination For Anti-Cd47 Antibodies In Cancer Therapy, Nicole Brittaney Pang
Identification Of Imiquimod As A Potential Combination For Anti-Cd47 Antibodies In Cancer Therapy, Nicole Brittaney Pang
Scripps Senior Theses
The avenues of targeted immunotherapy offers a promise of less toxic treatment options for those battling different forms of cancer. Specifically, the process of hijacking a patient’s own immune system to fight cancer from within versus using external treatments like chemotherapy which is extremely damaging to the patient. One such avenue includes the usage of monoclonal antibodies as an effective modality for immunotherapy. Cluster of Differentiation 47 (CD47), also known as the ‘don’t eat me signal’, aids in cell proliferation and evasion of phagocytosis and has been found to be a target for stopping tumorigenesis. Previous research has been successful …
Enhancing Chemosensitivity Of Lung Cancers By Manipulating The Tumor Microenvironment: Local Lung Delivery And Nanocarrier-Based Therapies, Hanming Zhang
Theses and Dissertations
Cancer is the second leading cause of death in United States causing an estimated six hundred thousand death in 2019. Among different types of cancer, lung cancer is the leading cause of cancer related death in both male and female. While targeted therapy and immunotherapy have shown promising clinical outcomes, currently there remain a significant proportion of patients who do not benefit from these strategies or who cannot tolerate them, making Pt based doublet chemotherapy still an indispensable component in almost all stages of treatment. However, partially due to the poor tumor distribution of small molecule drug, the development of …
Eftilagimod Alpha, A Soluble Lymphocyte Activation Gene-3 (Lag-3) Protein Plus Pembrolizumab In Patients With Metastatic Melanoma, Victoria Atkinson, Adnan Khattak, Andrew Haydon, Melissa Eastgate, Amitesh Roy, Prashanth Prithviraj, Christian Mueller, Chrystelle Brignone, Frederic Triebel
Eftilagimod Alpha, A Soluble Lymphocyte Activation Gene-3 (Lag-3) Protein Plus Pembrolizumab In Patients With Metastatic Melanoma, Victoria Atkinson, Adnan Khattak, Andrew Haydon, Melissa Eastgate, Amitesh Roy, Prashanth Prithviraj, Christian Mueller, Chrystelle Brignone, Frederic Triebel
Research outputs 2014 to 2021
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. BACKGROUND: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab. METHODS: The study was divided into two parts; parts A and B, where part A was the dose escalation part and part B was an extension part of the study. Patients with metastatic melanoma were treated with efti plus the standard dose of pembrolizumab. Blood samples were assayed to determine …
The Prognostic Impact Of Circulating Tumour Dna In Melanoma Patients Treated With Systemic Therapies—Beyond Braf Mutant Detection, Gabriela Marsavela, Peter A. Johansson, Michelle R. Pereira, Ashleigh C. Mcevoy, Anna L. Reid, Cleo Robinson, Lydia Warburton, Muhammad A. Khattak, Tarek M. Meniawy, Benhur Amanuel, Michael Millward, Nicholas K. Hayward, Melanie R. Ziman, Elin S. Gray, Leslie Calapre
The Prognostic Impact Of Circulating Tumour Dna In Melanoma Patients Treated With Systemic Therapies—Beyond Braf Mutant Detection, Gabriela Marsavela, Peter A. Johansson, Michelle R. Pereira, Ashleigh C. Mcevoy, Anna L. Reid, Cleo Robinson, Lydia Warburton, Muhammad A. Khattak, Tarek M. Meniawy, Benhur Amanuel, Michael Millward, Nicholas K. Hayward, Melanie R. Ziman, Elin S. Gray, Leslie Calapre
Research outputs 2014 to 2021
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. In this study, we evaluated the predictive value of circulating tumour DNA (ctDNA) to inform therapeutic outcomes in metastatic melanoma patients receiving systemic therapies. We analysed 142 plasma samples from metastatic melanoma patients prior to commencement of systemic therapy: 70 were treated with BRAF/MEK inhibitors and 72 with immunotherapies. Patient-specific droplet digital polymerase chain reaction assays were designed for ctDNA detection. Plasma ctDNA was detected in 56% of patients prior to first-line anti-PD1 and/or anti-CTLA-4 treatment. The detection rate in the immunotherapy cohort was comparably lower than those with BRAF inhibitors …